OABI

OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and expertise in ion channel discovery and screening. “We are pleased to enter into this important new relationship with Lilly,” said M.

OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript

OmniAb NASDAQ: OABI reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on Thursday, August 6, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast What:   OmniAb conference.

OmniAb NASDAQ: OABI reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Get OmniAb alerts:Sign UpPartner program progress drives revenue outperformance President and CEO Matt Foehr said the company continues to see partner programs derived from OmniAb's technologies move into the clinic and into later-stage development, which he described as the point where the licensing model translates into “clearer and more visible value” through potential future milestones and royalties.

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance. “OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidanc.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences over the coming weeks. H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate in a fireside chat on Wednesday, May 6th. Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28. Management will hold virtual one-on-one and small group meetings with investors on Thursday, May 28th. Jeff.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss first quarter 2026 financial results and business updates       Date:   Thursday, May 7, 2026       Time:   4:30 p.m. Easter.